血清尿酸相关基因变异对痛风风险的影响是否因体重指数而异?UK Biobank 分析
基于 UK Biobank 358,728 名参与者,按 BMI 分为低/正常、超重、肥胖三组,分析尿酸遗传风险评分(GRS)与痛风的关联及基因-BMI 交互作用。结果显示 GRS≥均值者在各组痛风患病率均更高,GRS 与痛风关联的 OR 在低/正常组为 2.89、超重组为 3.09、肥胖组为 2.65;肥胖组较超重组效应轻度减弱,但低/正常与超重、低/正常与肥胖组间无差异。结论:尿酸 GRS 对痛风风险在各 BMI 组均有强效应,肥胖者较超重者轻度减弱。
要点
- 尿酸 GRS≥均值者在低/正常、超重、肥胖组的痛风患病率均高于 GRS<均值者。
- GRS≥均值 vs <均值与痛风关联的 OR:低/正常 2.89,超重 3.09,肥胖 2.65。
- 肥胖组 GRS 对痛风风险效应较超重组轻度减弱,其余组间无差异。
核心结论
- 尿酸 GRS 与痛风的关联在肥胖个体中较超重个体轻度减弱,但遗传变异在超重和肥胖者中对痛风风险仍有强效应,与低/正常 BMI 者相似。
研究设计与样本
- 基于 UK Biobank 资源(n=358,728)的观察性分析,参与者按 BMI 分为低/正常(<25 kg/m2)、超重(≥25 且 <30 kg/m2)、肥胖(≥30 kg/m2)三组,采用 logistic 回归检验尿酸 GRS 与痛风的基因-BMI 交互作用。
主要发现
- GRS≥均值者痛风患病率在低/正常 BMI 组为 0.77% vs 0.27%,超重组为 3.02% vs 1.02%,肥胖组为 6.23% vs 2.49%(均与 GRS<均值者比较)。
- GRS≥均值 vs <均值与痛风关联的 OR:低/正常组 2.89(95%CI 2.42-3.47),超重组 3.09(95%CI 2.84-3.36),肥胖组 2.65(95%CI 2.46-2.86)。
- 肥胖组 GRS 对痛风风险的效应较超重组轻度减弱,但低/正常与超重组间、低/正常与肥胖组间 GRS 效应无差异。
临床怎么用
- 在超重和肥胖人群中,尿酸遗传风险评分较高者痛风风险显著升高,提示遗传易感性在这些 BMI 人群中仍有重要临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether urate-associated genetic variants differ in their influence on gout risk according to body mass index (BMI). METHODS: This research was conducted using the UK Biobank Resource (n = 358,728). Participants were divided into 3 groups: BMI <25 kg/m2 (low/normal), BMI ≥25 kg/m2 -<30 kg/m2 (overweight), and BMI ≥30 kg/m2 (obese). Gene-BMI interactions for gout association were tested by logistic regression using a urate genetic risk score (GRS). RESULTS: Compared to participants with a GRS less than the mean, the prevalence of gout was higher in those with a GRS greater than or equal to the mean in the low/normal BMI group (0.27% versus 0.77%), in the overweight BMI group (1.02% versus 3.02%), and in the obese BMI group (2.49% versus 6.23%). A GRS greater than or equal to the mean was positively associated with gout compared to a GRS less than the mean in the low/normal BMI group (odds ratio [OR] 2.89 [95% confidence interval (95% CI) 2.42-3.47]), in the overweight BMI group (OR 3.09 [95% CI 2.84-3.36]), and in the obese BMI group (OR 2.65 [95% CI 2.46-2.86]). There was a mildly attenuated effect of the GRS on gout risk in the obese BMI group compared to the overweight BMI group, but no difference in the effect of the GRS between the low/normal BMI and overweight BMI groups, nor between the low/normal BMI and obese BMI groups. CONCLUSION: The association of a urate GRS with gout is mildly attenuated in obese individuals compared to overweight individuals. However, genetic variants have a strong effect on gout risk in those with overweight and obese BMIs, with an effect similar to that observed in low/normal BMI.
引用
- Tai V, Narang RK, Gamble G, et al. Do Serum Urate-Associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank. Arthritis Rheumatol. 2020. PMID: 32017447. doi:10.1002/art.41219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。